Literature DB >> 19823168

Analysis of Aurora B kinase in non-Hodgkin lymphoma.

Takayuki Ikezoe1, Tamotsu Takeuchi, Jing Yang, Yoshihiro Adachi, Chie Nishioka, Mutsuo Furihata, H Phillip Koeffler, Akihito Yokoyama.   

Abstract

This study explored the levels of Aurora B, a key regulator of mitosis, in 71 lymph nodes and tumor specimens excised operatively from individuals with various types of non-Hodgkin lymphoma (NHLs). Immunohistochemical examination found that diffuse large B-cell lymphoma (10/21, 48%) and Burkitt lymphoma (BL) (6/7, 86%) cells highly (percentage of positive cells, >20%) expressed Aurora B in their nuclei. On the other hand, none of the low-grade B-cell lymphoma (n=20), except for one case of follicular lymphoma, highly expressed this protein kinase, suggesting that levels of Aurora B correlated with histological grade in B-cell NHLs (P<0.01). Exposure of BL/leukemia cells to AZD1152-HQPA in vitro, a selective inhibitor of Aurora B kinase, potently induced growth arrest and apoptosis in a caspase-dependent, as well as -independent manner. Moreover, AZD1152 synergistically enhanced the effects of vincristine (VCR) to induce growth arrest of these cells. Further experiments found that VCR increased levels of the p-Aurora B through the activation of c-Jun N-terminal kinase, which was blocked in the presence of AZD1152-HQPA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823168     DOI: 10.1038/labinvest.2009.106

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  19 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

Review 2.  The potential role of Aurora kinase inhibitors in haematological malignancies.

Authors:  Sherif S Farag
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

3.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

4.  p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.

Authors:  Takayuki Ikezoe; Jing Yang; Chie Nishioka; Akihito Yokoyama
Journal:  Int J Hematol       Date:  2009-12-16       Impact factor: 2.490

5.  Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.

Authors:  Wenqing Qi; Catherine Spier; Xiaobing Liu; Amit Agarwal; Laurence S Cooke; Daniel O Persky; Deyu Chen; Thomas P Miller; Daruka Mahadevan
Journal:  Leuk Res       Date:  2012-11-12       Impact factor: 3.156

6.  Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Authors:  Serena Marchetti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Roberto Mazzanti; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2013-01-13       Impact factor: 3.850

7.  Aurora B kinase in Hodgkin lymphoma: immunohistochemical pattern of expression in neoplastic Hodgkin and Reed-Sternberg cells.

Authors:  M Ioannou; E Kouvaras; E Stathakis; M Samara; G K Koukoulis
Journal:  J Mol Histol       Date:  2013-12-24       Impact factor: 2.611

8.  Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.

Authors:  Caterina Ierano; Arup R Chakraborty; Alina Nicolae; Julian C Bahr; Zhirong Zhan; Stefania Pittaluga; Susan E Bates; Robert W Robey
Journal:  Cell Cycle       Date:  2013-08-07       Impact factor: 4.534

9.  The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

Authors:  K Shiomitsu; E Sajo; C Rubin; I Sehgal
Journal:  Vet Comp Oncol       Date:  2013-06-13       Impact factor: 2.613

10.  Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.

Authors:  Ana Paula Zambuzi Cardoso Marsola; Belinda Pinto Simões; Leonardo Carvalho Palma; Maria Gabriela Berzoti-Coelho; Sandra Mara Burin; Fabíola Attié de Castro
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.